Purpose: We aimed to quantify fat-mass (FM) and muscle-mass (MM) changes over six months of liraglutide therapy and to identify predictors of disproportionate MM decline.Materials and Methods: In this retrospective observational cohort, adults with overweight/obesity receiving liraglutide underwent multifrequency bioelectrical impedance analysis (BIA) at baseline and 6 months. Patients were grouped by weight reduction (